Novel phosphodiesterase-5 inhibitors: current indications and future directions.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing pharmacology and clinical applications of PDE-5 inhibitors without systematic search or meta-analysis methodology.
What was done
This paper reviewed the clinical pharmacology, emerging indications, and therapeutic potential of phosphodiesterase-5 (PDE-5) inhibitors, focusing on sildenafil, tadalafil, and vardenafil across erectile dysfunction and broader cardiovascular or pulmonary conditions.
What was found
The abstract reports no quantitative data or statistical comparisons. It notes that newer agents (tadalafil, vardenafil) offer advantages over sildenafil including greater isoenzyme selectivity, absence of food effects on absorption, faster onset, and longer duration of action. It also highlights FDA approval of reformulated sildenafil for pulmonary arterial hypertension and notes emerging investigations in Raynaud's phenomenon, ventilation/perfusion mismatch disorders, heart failure, hypertension, and stroke.
Why it matters
It summarizes the expanding scope of PDE-5 inhibitors from erectile dysfunction into systemic and pulmonary vascular diseases driven by endothelial dysfunction.
Limits
The abstract describes a broad narrative overview without systematic review methodology, specific search criteria, study counts, or quantitative outcome data. Many mentioned cardiovascular indications reflect theoretical or early investigational uses rather than proven clinical efficacy.
Cited by
- supports Sildenafil (Viagra) was originally tested in clinical trials for angina and cardiovascular conditions before its erectile effects were observed.